NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Bio-Rad Laboratories, Inc. (BIO) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

BIO

$386.11

−$1.79 (−0.46%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BIO with… →

BIO Key Statistics

As of Sep 4, 2026
Trading
Open
$380.84
Previous Close
$387.90
Day's Range
376.20–386.78
52-Week Range
236.73–396.23
Volume
112.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.07
Valuation
Market Cap
$10.32B
P/E Ratio
46.97
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
38.50
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.01
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.99
EPS (ttm)Profit attributable to each share over the last twelve months.
8.22
Financials (FY)
Revenue (FY)
$2.58B+0.65%
Net Income (FY)
$759.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
8.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.68M
1-Year Return
+33.40%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
301.37K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.43%
2025−7.77%
2024+1.74%
2023−23.21%
2022−44.35%
2021+29.61%
2020+57.54%
2019+59.34%
2018−2.70%
2017+30.94%
2016 (partial year)+18.65%

As of September 4, 2026.

BIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.58B$759.90M29.4%
2024$2.57B−$1.84B−71.9%
2023$2.67B−$637.30M−23.9%
2022$2.80B−$3.63B−129.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.58B$1.34B$218.60M$759.90M29.4%
2024$2.57B$1.38B$269.00M−$1.84B−71.9%
2023$2.67B$1.43B$337.80M−$637.30M−23.9%
2022$2.80B$1.57B$475.10M−$3.63B−129.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BIO Valuation vs Medical Devices Median

Median of 151 stocks
MetricBIOMedical Devices medianvs median
P/E46.9726.8075% above
P/S ratio3.992.9834% above
Profit margin8.59%−1.69%10.3 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Bio-Rad Laboratories, Inc. (BIO) at $10.32B. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 7,450 employees.

Over the past 52 weeks the price has ranged from $236.73 to $396.23. The most recent close on file for BIO is $386.11, dated September 4, 2026. That is −$1.79 (−0.46%) against the previous close. The latest close sits 63.1% above that 52-week low.

Financial Health

In fiscal 2025, Bio-Rad Laboratories, Inc. reported revenue of $2.58B. That is +0.65% against the prior fiscal year, when revenue was $2.57B. The same year closed with net income of $759.90M. Profit margin runs at 8.59%. That is 10.3 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 8.22.

Across the 4 fiscal years on file, revenue moves from $2.80B in 2022 to $2.58B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 46.97. That is 75.26% above the Medical Devices median of 26.8. The forward P/E on file is 38.5. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.01. Measured against sales, the shares trade at 3.99 times revenue. On price-to-sales that is 33.97% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned +33.40%. Across 10 years the annualized return works out at +9.83%. The reported beta is 1.07. Annualized volatility over the trailing 10 years is 34.27%.

Growth & Income

No dividend is on file for BIO.

Across the complete calendar years on file, 2019 returned +59.34% and 2022 returned −44.35%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +27.43% year to date.

Peer Comparison

Bio-Rad Laboratories, Inc. (BIO) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bio-Rad Laboratories, Inc. BIO $10.32B 47.0
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Bio-Rad Laboratories, Inc. trades at a P/E of 47.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Visit website →